<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">18467721</PMID>
<DateCompleted>
<Year>2008</Year>
<Month>05</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>12</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Electronic">1527-7755</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>26</Volume>
<Issue>14</Issue>
<PubDate>
<Year>2008</Year>
<Month>May</Month>
<Day>10</Day>
</PubDate>
</JournalIssue>
<Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title>
<ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Phase II study of extended-dose temozolomide in patients with melanoma.</ArticleTitle>
<Pagination>
<MedlinePgn>2299-304</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2007.14.5292</ELocationID>
<Abstract>
<AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">We conducted a phase II trial of extended-dose temozolomide (TMZ) in patients with melanoma to test the hypothesis that the approximately 30% response rate observed in patients treated with extended-dose TMZ with antiangiogenic agents was caused by TMZ alone. We hypothesized that expression of methylguanine methyltransferase (MGMT) in the tumor would correlate with drug resistance to TMZ.</AbstractText>
<AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with stage IV or unresectable stage III melanoma were treated with TMZ 75 mg/m(2)/d for 6 weeks followed by a 2-week rest period. Cycles were repeated until progression. Patients were stratified by M1c disease or not. The primary end point was objective response proportion. MGMT expression was assessed by methylation-specific pyrosequencing of the promoter and by immunohistochemistry.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-nine patients (25 with M1c disease) were assessable. Three patients (12.5%) in each cohort experienced partial responses; there were no complete responses. Ten patients (21%) had stable disease lasting more than 24 weeks. Median time to progression was 3.3 months. Median survival was 10.1 months; survival was similar in the two cohorts. The estimated 18-month survival was 27%. There was no correlation between response and either immunohistochemistry staining for MGMT or for MGMT promoter methylation. Seventy-five percent of patients developed CD4(+) lymphopenia after three cycles.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Extended-dose TMZ therapy did not result in a 30% responses rate, which has been observed using extended-dose TMZ with antiangiogenic agents. Response did not correlate with MGMT expression or promoter methylation as a continuous variable, suggesting that other resistance mechanisms are important.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Rietschel</LastName>
<ForeName>Petra</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Wolchok</LastName>
<ForeName>Jedd D</ForeName>
<Initials>JD</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Krown</LastName>
<ForeName>Susan</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gerst</LastName>
<ForeName>Scott</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jungbluth</LastName>
<ForeName>Achim A</ForeName>
<Initials>AA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Busam</LastName>
<ForeName>Klaus</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Orlow</LastName>
<ForeName>Irene</ForeName>
<Initials>I</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Panageas</LastName>
<ForeName>Katherine</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Chapman</LastName>
<ForeName>Paul B</ForeName>
<Initials>PB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>J Clin Oncol</MedlineTA>
<NlmUniqueID>8309333</NlmUniqueID>
<ISSNLinking>0732-183X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017252">CD3 Complex</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7GR28W0FJI</RegistryNumber>
<NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.-</RegistryNumber>
<NameOfSubstance UI="D015254">DNA Modification Methylases</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.1.1.63</RegistryNumber>
<NameOfSubstance UI="C515491">MGMT protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 6.5.1.-</RegistryNumber>
<NameOfSubstance UI="D045643">DNA Repair Enzymes</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>YF1K15M17Y</RegistryNumber>
<NameOfSubstance UI="D000077204">Temozolomide</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018906">Antineoplastic Agents, Alkylating</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D017252">CD3 Complex</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000096">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015496">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018414">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015254">DNA Modification Methylases</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D045643">DNA Repair Enzymes</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D003606">Dacarbazine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D011401">Promoter Regions, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000077204">Temozolomide</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D025521">Tumor Suppressor Proteins</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>5</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18467721</ArticleId>
<ArticleId IdType="pii">26/14/2299</ArticleId>
<ArticleId IdType="doi">10.1200/JCO.2007.14.5292</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>